Showing 2431-2440 of 5771 results for "".
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- Kala Pharmaceuticals Announces FDA Approval of Inveltys for the Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-approval-of-inveltys-for-the-treatment-of-postoperative-inflammation-and-pain-following-ocular-surgery/2479913/Kala Pharmaceuticals announced that the FDA has approved Inveltys (loteprednol etabonate ophthalmic suspension 1%) for the treatment of postoperative inflammation and pain following ocular surgery. Inveltys is the first twice-daily (BID) ocular corticosteroid approved for this indication.
- MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2479927/MeiraGTx Holdings announced that the FDA has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGB3 gene. ACHM is an inherited retinal disease that severely limits a person’s sight
- EyeGate Announces Enrollment of First Patient in PRK Pilot Studyhttps://modernod.com/news/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/2479928/EyeGate Pharmaceuticals announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery.
- Topcon Announces Date for 3rd Annual ISSOCT Conferencehttps://modernod.com/news/topcon-announces-date-for-3rd-annual-issoct-conference/2479931/Topcon Medical Systems has announced that the 3rd Annual ISSOCT Conference will be held on February 10-11, 2019 at the Sanibel Harbour Marriott Resort in Fort Myers, Florida. The world’s leading ophthalmologist
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarringhttps://modernod.com/news/rxi-pharmaceuticals-announces-positive-results-from-phase-1-2-trial-with-rxi-109-for-retinal-scarring/2479959/RXi Pharmaceuticals announced positive results with RXI-109 in a phase 1/2 clinical trial. RXI-109-1501 is an open-label, multidose, dose escalation study with three dose cohorts, enrolled sequentially, evaluating the safety and tolerability of RXI-109 injections in the eye of subjects with advan
- International Sports Vision Association Announces Appointment of Gary Esterow as Executive Directorhttps://modernod.com/news/international-sports-vision-association-announces-appointment-of-gary-esterow-as-executive-director/2479964/The International Sports Vision Association (ISVA), an organization of optometrists, athletic trainers, therapists, physicians and sports teams dedicated to evaluating, training, and improving vision performance in athletes, announced the appointment of Gary Esterow as Executive Director.
- ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10/2479967/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft